230 related articles for article (PubMed ID: 23778530)
1. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence.
Hirata K; Suzuki H; Imaeda H; Matsuzaki J; Tsugawa H; Nagano O; Asakura K; Saya H; Hibi T
Br J Cancer; 2013 Jul; 109(2):379-86. PubMed ID: 23778530
[TBL] [Abstract][Full Text] [Related]
2. Expression of microRNA-328 Functions as a Biomarker for Recurrence of Early Gastric Cancer (EGC) After Endoscopic Submucosal Dissection (ESD) by Modulating CD44.
Xue HG; Yang AH; Sun XG; Lu YY; Tian ZB
Med Sci Monit; 2016 Dec; 22():4779-4785. PubMed ID: 27923017
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of early gastric cancer diagnosed as mixed adenocarcinoma after endoscopic submucosal dissection.
Han JP; Hong SJ; Kim HK
J Gastroenterol Hepatol; 2015 Feb; 30(2):316-20. PubMed ID: 25351280
[TBL] [Abstract][Full Text] [Related]
5. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
6. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.
Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874
[TBL] [Abstract][Full Text] [Related]
7. The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.
Akamine T; Tagawa T; Ijichi K; Toyokawa G; Takamori S; Hirai F; Okamoto T; Oda Y; Maehara Y
Ann Surg Oncol; 2019 May; 26(5):1544-1551. PubMed ID: 30798450
[TBL] [Abstract][Full Text] [Related]
8. CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer.
Go SI; Ko GH; Lee WS; Kim RB; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2016 Jan; 48(1):142-52. PubMed ID: 25779358
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Cyclin D1 and CD44 Expression in Gastric Adenocarcinoma.
Ibrahim HM; AbdElbary AM; Mohamed SY; Elwan A; Abdelhamid MI; Ibrahim A
J Gastrointest Cancer; 2019 Sep; 50(3):370-379. PubMed ID: 29497929
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of additional surgery after noncurative endoscopic resection in patients with early gastric cancer.
Eom BW; Kim YI; Kim KH; Yoon HM; Cho SJ; Lee JY; Kim CG; Kook MC; Kim YW; Nam BH; Ryu KW; Choi IJ
Gastrointest Endosc; 2017 Jan; 85(1):155-163.e3. PubMed ID: 27460389
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer.
Kurozumi K; Nishida T; Nakao K; Nakahara M; Tsujimoto M
World J Surg; 1998 Aug; 22(8):853-7; discussion 857-8. PubMed ID: 9673558
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center experience.
Choi MK; Kim GH; Park DY; Song GA; Kim DU; Ryu DY; Lee BE; Cheong JH; Cho M
Surg Endosc; 2013 Nov; 27(11):4250-8. PubMed ID: 23765426
[TBL] [Abstract][Full Text] [Related]
13. Early Gastric Cancers: Is CT Surveillance Necessary after Curative Endoscopic Submucosal Resection for Cancers That Meet the Expanded Criteria?
Choi KS; Kim SH; Kim SG; Han JK
Radiology; 2016 Nov; 281(2):444-453. PubMed ID: 27243549
[TBL] [Abstract][Full Text] [Related]
14. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.
Kakehashi A; Ishii N; Sugihara E; Gi M; Saya H; Wanibuchi H
Cancer Sci; 2016 May; 107(5):609-18. PubMed ID: 26882440
[TBL] [Abstract][Full Text] [Related]
15. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis.
Yong CS; Ou Yang CM; Chou YH; Liao CS; Lee CW; Lee CC
BMC Gastroenterol; 2012 Jul; 12():95. PubMed ID: 22839505
[TBL] [Abstract][Full Text] [Related]
16. CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues.
Yamakawa Y; Kusuhara M; Terashima M; Kinugasa Y; Sugino T; Abe M; Mochizuki T; Hatakeyama K; Kami K; Yamaguchi K
Biomed Res; 2017; 38(1):41-52. PubMed ID: 28239031
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of endoscopic submucosal dissection for early gastric cancer with special reference to validation for curability criteria.
Goto O; Fujishiro M; Kodashima S; Ono S; Omata M
Endoscopy; 2009 Feb; 41(2):118-22. PubMed ID: 19214889
[TBL] [Abstract][Full Text] [Related]
18. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study.
Isomoto H; Shikuwa S; Yamaguchi N; Fukuda E; Ikeda K; Nishiyama H; Ohnita K; Mizuta Y; Shiozawa J; Kohno S
Gut; 2009 Mar; 58(3):331-6. PubMed ID: 19001058
[TBL] [Abstract][Full Text] [Related]
19. Bone metastasis from early gastric cancer following non-curative endoscopic submucosal dissection.
Kawabata H; Oda I; Suzuki H; Nonaka S; Yoshinaga S; Katai H; Taniguchi H; Kushima R; Saito Y
World J Gastroenterol; 2013 Aug; 19(30):5016-20. PubMed ID: 23946610
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification and management of non-curative resection after endoscopic submucosal dissection for early gastric cancer.
Han JP; Hong SJ; Kim HK; Lee YN; Lee TH; Ko BM; Cho JY
Surg Endosc; 2016 Jan; 30(1):184-9. PubMed ID: 25829067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
